Skip to content

Study · Not a test of the peptide alone · 1991

1 result

Synthesis of rat parathymosin alpha fragment 1-28 and examination of its inhibitory activity towards the restoring activity of thymosin alpha 1 on the impaired T-lymphocytes of uremic patients.

Abiko T, Sekino H

Chemical & pharmaceutical bulletin1 Oct 1991Cited by 2 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In T-lymphocytes from uremic patients, parathymosin alpha fragment 1-28 given together with thymosin alpha‑1 appeared to suppress the restoring effect of thymosin alpha‑1.

    In plain wordsIn lab tests on immune cells, the parathymosin fragment seemed to block the restoring effect of thymosin alpha‑1.

    Outcome
    DecreaseFragment 1-28 effect on thymosin alpha 1 restoring activity
    Study

    humann: not reported in source

    T-lymphocytes isolated from uremic patients
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    but when it was administered together with thymosin alpha 1, it appeared to suppress the restoring effect of the thymosin alpha 1 on the impaired T-lymphocytes of uremic patients.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.